Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | EIF4E | P06730 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150205 | 1.00 | LMNA (0.63) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL27516530 | 1.00 | LMNA (0.63) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL11672982 | 0.83 | ALDH1A1 (0.56) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL6683106 | 0.82 | LMNA (0.60) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL11671849 | 0.78 | PI4KA (0.46) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL24547631 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL12041982 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL21842489 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL26561 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL11910472 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1190198-C | Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs in activated T lymphocytes | ICN PHARMACEUTICALS CO (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1240899-A2 | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | ICN Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-1174141-A2 | Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes | ICN Pharmaceuticals, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1027359-A4 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-1027359-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| CN-1209747-A | Modulation of TH1/TH2 cytokine expression by Ribavirin and Ribavirin analogs in activated T lymphocytes | ICN PHARMACEUTICALS CO (US) | 1999-03-03 | — | — | CN | disclosed |
| WO-1998016186-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-4021542-A | Derivatives of hydrazino-monosaccharides and aldohexoses which are useful as intermediates for preparing compounds or as compounds which lower the uric acid | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | LMNA 1677/4885SMN1; SMN2 724/4885ALDH1A1 592/4885 |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | LMNA 1677/4885SMN1; SMN2 724/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.